Latest Hepatitis News

CDC proposes expansion of hepatitis C guidelinesCDC is proposing an expansion of its current hepatitis C risk-based guidelines to include a simple, one-time blood test ?for anyone born from 1945 through 1965.

Advanced Biological Laboratories' DeepChek® and ViroScore® Suite Clinical Genotyping Solutions For Personalized Treatment of HIV Receive CE Mark for In Vitro Diagnostic UseAdvanced Biological Laboratories (ABL) announced today that DeepChek® and ViroScore® Suite clinical genotyping solutions are now CE-IVD (In Vitro Diagnostics) approved for commercial use in Europe and other countries that recognise CE certification. This approval is further validating the use of our next generation sequencing (NGS) downstream an...

Screen all baby boomers for hepatitis C, advises US public health agencyOne in 30 US baby boomers is infected with hepatitis C and doesn’t know it. They should all be tested for the virus at least once, said the US Centers for Disease Control and Prevention (CDC).The...

Vertex Appoints David Altshuler, M.D., Ph.D., to its Board of DirectorsVertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that David Altshuler, M.D., Ph.D., joined its board of directors as an independent director. Dr. Altshuler was appointed to the class of directors whose term expires in 2015. With the addition of Dr. Altshuler, the Vertex board consists of 9 members.

Canine VacciCheck(R) Developed by Biogal was Highly Recommended in Articles Published in the Chicago Tribune and on BBC RadioKIBBUTZ GALED, Israel, May 24, 2012 /PRNewswire/ -- An interview recently published in the Chicago Tribune, addresses the use of Canine VacciCheck®, developed by Biogal, as a way to titer test dogs for core canine vaccines. In the article, Professor Schultz from the University of Wisconsin refers to Canine VacciCheck®: "One way to insure comfort for pet owners and veterinarians alike i...

UK's NICE Gives Thumbs Up to New Prostate Cancer Treatment Following Price DropLatest Decision from UK Health Authority Underscores Therapeutic Product Innovation Conundrum, according to RegLink News Washington, DC (PRWEB) May 24, 2012 The UK’s reimbursement watch dog, the National Institute for Clinical Excellence (NICE), has changed its mind and announced that it will after all propose the use by the National Health Service (NHS) of Janssen’s life extending new oral p...

Two senior moves at Red Door CommunicationsRed Door Communications has bolstered its senior account handling team by re-hiring Sarah Aldridge as account director. Aldridge (pictured) has spent the last two years in her native Australia, working at Sydney-based healthcare communications...

Therapure Biopharma Receives BIOTECanada Gold Leaf AwardTherapure Biopharma Inc. is pleased to announce today that it has been awarded the Gold Leaf Award for Emerging Company of the Year by BIOTECanada in the Health Biotech Category for 2012. Therapure has been recognized as an outstanding emerging health company for the potential of its unique biomanufacturing capabilities as well as its highly innovative...

Radioembolization Spheres to See Strong Growth in China Through 2016According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, the embolization particle segment of the Asia Pacific transcatheter embolization and occlusion (TEO) device market will expand rapidly through 2016, driven by innovations that have led to new uses in the treatment of peripheral vascular tumors, par...

Inhibition of Hepatitis C Virus Replication by Intracellular Delivery of Multiple siRNAs by Nanosomes

CORRECTION: Gay men have higher liver-related mortality from HBV than HCVNEW YORK (Reuters Health) - In a population of men who have sex with men (MSM) -- with a high prevalence of HIV infection -- chronic hepatitis B virus (HBV) led to twice as many liver-related deaths as chronic hepatitis C virus (HCV), researc...

HCV Patients May Be Able to Delay TherapySAN DIEGO (MedPage Today) -- Hepatitis C patients without significant fibrosis may be able to delay triple therapy and wait for simpler, shorter, and potentially all-oral regimens that are currently under investigation, researchers said here.

Hepatitis C Causing Liver Damage in Greater Numbers: StudyTUESDAY, May 22 -- Hundreds of thousands of Americans infected with chronic hepatitis C virus could develop potentially life-threatening liver complications over the next few years, according to a new study. Researchers evaluated medical insurance......

22 Biopharma Stocks With Breakout Potential in 2012BOSTON (TheStreet) -- Drug approval decisions garner big headlines, but savvy and successful biotech investors know that making smart trading decisions ahead of important clinical trial results is the ticket to banking serious coin. The market value...

Safe in Common to Exhibit at National Teaching Institute and Critical Care ExpositionORLANDO, Fla., May 22, 2012 /PRNewswire/ -- Safe in Common, a non-profit organization of healthcare safety advocates, today announced it will exhibit at the National Teaching Institute and Critical Care Exposition (NTI), which will be held in Orlando, Fla. from May 19 - 24. During its year-long Needlestick Safety Advocacy Tour, Safe in Common (SIC) is engaging healthcare personnel at confere...

Project ECHO: Bringing Medical Specialists Together to Discuss New HCV Therapies to Treat HCVProject ECHO™, University of New Mexico Office of Continuing Education, and Consensus Medical Communications are pleased to announce the annual Project ECHO™: Knowledge Networks for New HCV Therapies live teleconference continuing medical education weekly activity. Englewood, CO (PRWEB) May 22, 2012 Project ECHO™, University of New Mexico Office of Continuing Education, and Consensus Medica...

New research examines impact of liver disease(Digestive Disease Week) Research being presented at Digestive Disease Week® offers insights into the progression of diseases leading to liver damage, which affect diverse populations, including young people. Studies show that the increasing rates o...

CDC Announces First Ever National Hepatitis Testing Day and Proposes that All Baby Boomers Be Tested Once for Hepatitis COn the eve of the first ever National Hepatitis Testing Day (May 19), the Centers for Disease Control and Prevention is issuing draft guidelines proposing that all U.S. baby boomers get a one-time test for the hepatitis C virus. One in 30 baby...

Since Gaining European Authority Approval for Victrelis in July and Incivo in September, Protease Inhibitor Share Has Penetrated Nearly One-Third of the Genotype 1 Market and is Anticipated to Significantly Increase Over the Next Six MonthsBioTrends Research Group, one of the world’s leading research and advisory firms for specialized biopharmaceutical issues, finds that Vertex and Janssen / Tibotec’s Incivo (telaprevir) and Merck / Roche’s Victrelis (boceprevir) are quickly being adopted as the new standard of care in genotype 1 hepatitis C (HCV) patients in the EU5. Since their Europ...

All "baby boomers" should be tested once for hepatitis C, says USA's CDCOn the eve of the first ever National Hepatitis Testing Day (May 19), the US Centers for Disease Control and Prevention issued draft guidelines proposing that all US "baby boomers" get a one-time test for the hepatitis C virus. Current guidelines onl...

Achillion Announces Additional Proof-of-Concept Data With ACH-2684 for the Treatment of Hepatitis CNEW HAVEN, Conn., May 21, 2012 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported proof-of-concept data from a Phase 1b clinical trial demonstrating that patients with chronic hepatitis C (HCV) genotype 1 (GT 1) treated with ACH-2684, a second-generation protease inhibitor, achieved a mean maximum 3.73 log10 reduction in HCV RNA after three-day 400 mg monotherapy wit...

Test Baby Boomers for Hepatitis C, Says CDCBy Steven Reinberg HealthDay Reporter FRIDAY, May 18 (HealthDay News) -- The U.S. Centers for Disease Control and Prevention wants all Americans born between 1945 and 1965 -- the baby boom generation -- tested for hepatitis C. Most c...

U.S. Suggests All Baby Boomers Should Get Tested for Hepatitis CU.S. health officials are proposing all baby boomers get tested for hepatitis C, because theyre five times more likely than other adults to have the potentially fatal liver virus and many might not know theyre at risk.

Test Baby Boomers for Hepatitis C, Says CDCFRIDAY, May 18 -- The U.S. Centers for Disease Control and Prevention wants all Americans born between 1945 and 1965 -- the baby boom generation -- tested for hepatitis C. Most cases of the potentially deadly disease occur in this age group, and...

CDC to baby boomers: Get tested for hepatitis CU.S. health officials want all baby boomers to get tested for hepatitis C.The Centers for Disease Control and Prevention on Friday released draft recommendations calling for all baby boomers to get a one-time blood test for the liver disease. That's...

0 1 2 3 4 ›»

buy Hepatitis market research data and corporate reports now Advertisement